Skip to content
2000
Volume 33, Issue 3
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Cholesteatoma, an abnormal accumulation of keratinized squamous epithelium in the middle ear, occurs as a locally invasive but histologically benign lesion. Its capacity for bone erosion leads to significant complications, including hearing loss, facial nerve paralysis, and intracranial infections. Chronic inflammation is central to its pathogenesis, with proinflammatory mediators like TNF-α, IL-1β, and IL-6 activating signaling pathways, such as NF-κB, JAK/STAT, and MAPK. These pathways contribute to epithelial hyperproliferation and extracellular matrix degradation mediated by Matrix Metalloproteinases (MMPs). Dysregulation of epithelial cell behavior, involving altered keratinocyte function and reduced E-cadherin-mediated adhesion, may facilitate lesion formation and expansion. Furthermore, aberrant signaling involving growth factors (, EGF, TGF-β) and dysregulation of osteoclast activity the RANKL pathway contribute to enhanced bone erosion and tissue invasion. Emerging research highlights potential roles of the c-MYC proto-oncogene, microRNAs, and Sonic hedgehog signaling in disease progression, offering deeper insights into the pathogenesis. Current management primarily involves surgical excision, yet high recurrence rates emphasize the need for adjunctive therapeutic strategies. Potential future directions include modulating key pathways, such as NF-κB, MMP activity, and RANKL signaling, as well as exploring interventions related to growth factors and cell adhesion. Integrating molecular insights with clinical research is essential for developing strategies to reduce recurrence and improve patient outcomes.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673404489250515074316
2025-05-19
2026-03-07

  • From This Site

    /content/journals/cmc/10.2174/0109298673404489250515074316
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. HamedM.A. NakataS. SayedR.H. UedaH. BadawyB.S. NishimuraY. KojimaT. IwataN. AhmedA.R. DahyK. KondoN. SuzukiK. Pathogenesis and bone resorption in acquired cholesteatoma: Current knowledge and future prospectives.Clin. Exp. Otorhinolaryngol.20169429830810.21053/ceo.2015.0166227440129
     [Google Scholar]
  2. SchürmannM. GoonP. SudhoffH. Review of potential medical treatments for middle ear cholesteatoma.Cell Commun. Signal.202220114810.1186/s12964‑022‑00953‑w36123729
     [Google Scholar]
  3. ManiuA.P. HarabagiuO. SchreplerM. CătanăA. FănuţăB. MogoantăC.A. Molecular biology of cholesteatoma.Rom. J. Morphol. Embryol.201455171324715159
     [Google Scholar]
  4. KhairkarM. DeshmukhP. MaityH. DeotaleV. Chronic suppurative otitis media: A comprehensive review of epidemiology, pathogenesis, microbiology, and complications.Cureus2023158e4372910.7759/cureus.4372937727177
     [Google Scholar]
  5. LouwL. Acquired cholesteatoma: Summary of the cascade of molecular events.J. Laryngol. Otol.2013127654254910.1017/S002221511300060123656971
     [Google Scholar]
  6. SzczepanskiM.J. LuczakM. OlszewskaE. Molinska-GluraM. ZagorM. KrzeskiA. SkarzynskiH. MisiakJ. DzamanK. BilusiakM. KopecT. LeszczynskaM. WitmanowskiH. WhitesideT.L. Molecular signaling of the HMGB1/RAGE axis contributes to cholesteatoma pathogenesis.J. Mol. Med.201593330531410.1007/s00109‑014‑1217‑325385222
     [Google Scholar]
  7. ImaiR. SatoT. IwamotoY. HanadaY. TeraoM. OhtaY. OsakiY. ImaiT. MorihanaT. OkazakiS. OshimaK. OkuzakiD. KatayamaI. InoharaH. Osteoclasts modulate bone erosion in cholesteatoma via RANKL signaling.J. Assoc. Res. Otolaryngol.201920544945910.1007/s10162‑019‑00727‑131254133
     [Google Scholar]
  8. KarthikeyanM. MohanV. PurohitP. SharmaV. SoniK. ChoudhuryB. BanerjeeM. ElhenceP. GoyalA. Unveiling the aggressiveness of cholesteatoma: Associating MERI with miRNA-21 & IL-6 expression.Laryngoscope2025135136637210.1002/lary.3173739390643
     [Google Scholar]
  9. SiY. ChenY.B. ChenS.J. ZhengY.Q. LiuX. LiuY. JiangH.L. XuG. LiZ.H. HuangQ.H. XiongH. ZhangZ.G. TLR4 drives the pathogenesis of acquired cholesteatoma by promoting local inflammation and bone destruction.Sci. Rep.2015511668310.1038/srep1668326639190
     [Google Scholar]
  10. OlszewskaE. WagnerM. Bernal-SprekelsenM. EbmeyerJ. DazertS. HildmannH. SudhoffH. Etiopathogenesis of cholesteatoma.Eur. Arch. Otorhinolaryngol.2004261162410.1007/s00405‑003‑0623‑x12835944
     [Google Scholar]
  11. DambergsK. SumeragaG. PilmaneM. Morphopathogenesis of adult acquired cholesteatoma.Medicina202359230610.3390/medicina5902030636837507
     [Google Scholar]
  12. OlszewskaE. MatulkaM. MroczkoB. PryczyniczA. KemonaA. SzmitkowskiM. MierzwinskiJ. PietrewiczT. Diagnostic value of matrix metalloproteinase 9 and tissue inhibitor of matrix metalloproteinases 1 in cholesteatoma.Histol. Histopathol.201631330731510.14670/HH‑11‑67726490574
     [Google Scholar]
  13. KanT. UedaH. TakaharaT. TsuchiyaY. KishimotoM. UchidaY. OgawaT. OhashiW. TsuzukiT. FujimotoY. Association of matrix metalloproteinase-2 mRNA expression with subtypes of pediatric cholesteatoma.BioMed Res. Int.20212021664489710.1155/2021/664489733778077
     [Google Scholar]
  14. MiG.X. NingY. SunK. TaoL.L. MaX.F. WangL.Q. Expression of matrix metalloproteinase in cholesteatoma epithelium of patients with cholesteatoma otitis media.J. Biol. Regul. Homeost. Agents20193361843184810.23812/19‑140‑L31713404
     [Google Scholar]
  15. RezendeC.E.B. SoutoR.P. RapoportP.B. CamposL. GeneratoM.B. Cholesteatoma gene expression of matrix metalloproteinases and their inhibitors by RT-PCR.Rev. Bras. Otorrinolaringol.201278311612110.1590/S1808‑8694201200030001922714856
     [Google Scholar]
  16. Suchozebrska-JesionekD. SzymańskiM. KurzepaJ. GołabekW. Stryjecka-ZimmerM. Gelatinolytic activity of matrix metalloproteinases 2 and 9 in middle ear cholesteatoma.J. Otolaryngol. Head Neck Surg.200837562863219128667
     [Google Scholar]
  17. OttavianiF. NegliaC.B. BertiE. Francesco Ottaviani, Cesare Bartolo Cytokines and adhesion molecules in middle ear cholesteatoma. A role in epithelial growth?Acta Otolaryngol.1999119446246710.1080/0001648995018100810445062
     [Google Scholar]
  18. BujiaJ. SudhoffH. HollyA. HildmannH. KastenbauerE. Immunohistochemical detection of proliferating cell nuclear antigen in middle ear cholesteatoma.Eur. Arch. Otorhinolaryngol.19962531-2212410.1007/BF001766978932424
     [Google Scholar]
  19. HollyA. SittingerM. BujiaJ. Immunohistochemical demonstration of c-myc oncogene product in middle ear cholesteatoma.Eur. Arch. Otorhinolaryngol.1995252636636910.1007/BF001782798679157
     [Google Scholar]
  20. AdriaansensC. BekkersS. AartsM.C.J. Determinants influencing cholesteatoma recurrence in daily practice: A retrospective analysis.J. Laryngol. Otol.2022136211912410.1017/S002221512100354635081995
     [Google Scholar]
  21. MoritaY. TakahashiK. IzumiS. KubotaY. OhshimaS. YamamotoY. TakahashiS. HoriiA. Risk factors of recurrence in pediatric congenital cholesteatoma.Otol. Neurotol.201738101463146910.1097/MAO.000000000000158728953605
     [Google Scholar]
  22. SchürmannM. OppelF. ShaoS. Volland-ThurnV. KaltschmidtC. KaltschmidtB. ScholtzL.U. SudhoffH. Chronic inflammation of middle ear cholesteatoma promotes its recurrence via a paracrine mechanism.Cell Commun. Signal.20211912510.1186/s12964‑020‑00690‑y33627146
     [Google Scholar]
  23. CantoneE. Di NolaC. De CorsoE. CavaliereM. GrimaldiG. FetoniA.R. MottaG. Endotyping of cholesteatoma: Which molecular biomarkers? A systematic review.J. Pers. Med.2022128134710.3390/jpm1208134736013295
     [Google Scholar]
  24. BelákováP. StárekI. SalzmanR. HyravýM. Chronic inflammation of the middle ear with cholesteatoma.Cas. Lek. Cesk.2019158623523931931582
     [Google Scholar]
  25. VitaleR.F. RibeiroF.A.Q. The role of tumor necrosis factor -alpha (TNF-α) in bone resorption present in middle ear cholesteatoma.Rev. Bras. Otorrinolaringol.200773111712110.1016/S1808‑8694(15)31133‑217505610
     [Google Scholar]
  26. AynaliG. TuzM. BagcıÖ. KılıçkayaM. Is there a systemıc inflammatory effect of cholesteatoma?Int. Arch. Otorhinolaryngol.2016211424510.1055/s‑0036‑158436328050207
     [Google Scholar]
  27. WiatrA. JobK. SkładzieńJ. WiatrM. Chronic suppurative otitis media with cholesteatoma and chronic otitis media with granulation by scanning electron microscopy based on analysis of 140 patients.Otolaryngol. Pol.20217521510.5604/01.3001.0014.701133949967
     [Google Scholar]
  28. XieS. JinL. FuJ. YuanQ. YinT. RenJ. LiuW. PTHrP participates in the bone destruction of middle ear cholesteatoma via promoting macrophage differentiation into osteoclasts induced by RANKL.Zhong Nan Da Xue Xue Bao Yi Xue Ban202449565566610.11817/j.issn.1672‑7347.2024.23048239174879
     [Google Scholar]
  29. HeoK.W. NohM. HurD.Y. HongT.U. ParkS.Y. KimW.J. Bone destruction in chronic otitis media is not mediated by the RANKL pathway or estrogen receptor-alpha.Sci. Prog.2023106336850423119920410.1177/0036850423119920437697808
     [Google Scholar]
  30. SiwikD.A. ColucciW.S. Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium.Heart Fail. Rev.200491435110.1023/B:HREV.0000011393.40674.1314739767
     [Google Scholar]
  31. HamajimaY. KomoriM. PreciadoD.A. ChooD.I. MoribeK. MurakamiS. OndreyF.G. LinJ. The role of inhibitor of DNA-binding (Id1) in hyperproliferation of keratinocytes: The pathological basis for middle ear cholesteatoma from chronic otitis media.Cell Prolif.201043545746310.1111/j.1365‑2184.2010.00695.x20887552
     [Google Scholar]
  32. LiuW. YinT. RenJ. LiL. XiaoZ. ChenX. XieD. Activation of the EGFR/Akt/NF-κB/cyclinD1 survival signaling pathway in human cholesteatoma epithelium.Eur. Arch. Otorhinolaryngol.2014271226527310.1007/s00405‑013‑2403‑623463347
     [Google Scholar]
  33. PreciadoD. CaicedoE. JhanjeeR. SilverR. HarrisG. JuhnS.K. ChooD.I. OndreyF. Pseudomonas aeruginosa lipopolysaccharide induction of keratinocyte proliferation, NF-kappa B, and cyclin D1 is inhibited by indomethacin.J. Immunol.200517452964297310.4049/jimmunol.174.5.296415728509
     [Google Scholar]
  34. WesterbergJ. TideholmE. PiersialaK. DrakskogC. GeorénS.K. Mäki-TorkkoE. CardellL.O. JAK/STAT dysregulation with SOCS1 overexpression in acquired cholesteatoma-adjacent mucosa.Otol. Neurotol.2021421e94e10010.1097/MAO.000000000000285033201080
     [Google Scholar]
  35. EskiizmirG. VatanseverH.S. ÖzgürE. AslanA. TanyeriG. GözüaçıkD. ÖzbilginM.K. CingiC. Jak-Stat signaling pathway may play a role in the pathogenesis of cholesteatoma.Am. J. Otolaryngol.201435213013610.1016/j.amjoto.2013.10.00524321752
     [Google Scholar]
  36. WajantH. PfizenmaierK. ScheurichP. Tumor necrosis factor signaling.Cell Death Differ.2003101456510.1038/sj.cdd.440118912655295
     [Google Scholar]
  37. TeitelbaumS.L. Bone resorption by osteoclasts.Science200028954841504150810.1126/science.289.5484.150410968780
     [Google Scholar]
  38. EpsleyS. TadrosS. FaridA. KargilisD. MehtaS. RajapakseC.S. The effect of inflammation on bone.Front. Physiol.20211151179910.3389/fphys.2020.51179933584321
     [Google Scholar]
  39. JeongJ.H. ParkC.W. TaeK. LeeS.H. ShinD.H. KimK.R. ParkY.W. Expression of RANKL and OPG in middle ear cholesteatoma tissue.Laryngoscope200611671180118410.1097/01.mlg.0000224345.59291.da16826057
     [Google Scholar]
  40. UdagawaN. KoideM. NakamuraM. NakamichiY. YamashitaT. UeharaS. KobayashiY. FuruyaY. YasudaH. FukudaC. TsudaE. Osteoclast differentiation by RANKL and OPG signaling pathways.J. Bone Miner. Metab.2021391192610.1007/s00774‑020‑01162‑633079279
     [Google Scholar]
  41. KuczkowskiJ. Sakowicz-BurkiewiczM. Iżycka-ŚwieszewskaE. MikaszewskiB. PawełczykT. Expression of tumor necrosis factor-α, interleukin-1α, interleukin-6 and interleukin-10 in chronic otitis media with bone osteolysis.ORL J. Otorhinolaryngol. Relat. Spec.2011732939910.1159/00032383121311206
     [Google Scholar]
  42. ZhangW. BadoI.L. HuJ. WanY.W. WuL. WangH. GaoY. JeongH.H. XuZ. HaoX. LegeB.M. Al-OuranR. LiL. LiJ. YuL. SinghS. LoH.C. NiuM. LiuJ. JiangW. LiY. WongS.T.C. ChengC. LiuZ. ZhangX.H.F. The bone microenvironment invigorates metastatic seeds for further dissemination.Cell2021184924712486.e2010.1016/j.cell.2021.03.01133878291
     [Google Scholar]
  43. WuY. TangX. ShaoW. LuY. Effect of CT manifestations of cholesteatoma on MMP-2, MMP-9 and IL-6 in the serum of patients.Exp. Ther. Med.20191764441444610.3892/etm.2019.748431086579
     [Google Scholar]
  44. MoralesD.S.R. PenidoN.O. Guerreiro da SilvaI.D.C. StávaleJ.N. GuilhermeA. FukudaY. Matrix Metalloproteinase 2: An important genetic marker for cholesteatomas.Rev. Bras. Otorrinolaringol.2007731515710.1016/S1808‑8694(15)31122‑817505599
     [Google Scholar]
  45. ÖzdemirÇ. KuzuS. ŞenolY. YiğitT. GüldünE. BucakA. UluŞ. TokyolÇ. A role for mast cell-mediated antibodies in the formation of cholesteatoma and cholesteatoma-induced bone erosion.Diagnostics202313345510.3390/diagnostics1303045536766559
     [Google Scholar]
  46. MoghaddamY.J. GermiM.N. AlamdaryS.N. EmamiM. ShanehbandiD. SoofiyaniS.R. Matrix metallopeptidase 9 expression in tumoral and marginal tissues of cholesteatoma.ImmunoAnalysis20244810.34172/ia.4084
     [Google Scholar]
  47. YoshikawaM. KojimaH. YaguchiY. OkadaN. SaitoH. MoriyamaH. Cholesteatoma fibroblasts promote epithelial cell proliferation through overexpression of epiregulin.PLoS One201386e6672510.1371/journal.pone.006672523826119
     [Google Scholar]
  48. RolesiR. PacielloF. PaludettiG. De CorsoE. SergiB. FetoniA. Study of angiogenic, pro-apoptotic, and pro-inflammatory factors in congenital and acquired cholesteatomas.J. Pers. Med.2023138118910.3390/jpm1308118937623440
     [Google Scholar]
  49. Yamamoto-FukudaT. AkiyamaN. Keratinocyte growth factor signaling promotes stem/progenitor cell proliferation under p63 expression during middle ear cholesteatoma formation.Curr. Opin. Otolaryngol. Head Neck Surg.202028529129510.1097/MOO.000000000000065532796271
     [Google Scholar]
  50. LiuW. RenH. RenJ. YinT. HuB. XieS. DaiY. WuW. XiaoZ. YangX. XieD. The role of EGFR/PI3K/Akt/cyclinD1 signaling pathway in acquired middle ear cholesteatoma.Mediators Inflamm.201320131910.1155/2013/65120724311896
     [Google Scholar]
  51. ZhangW. LiuH.T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells.Cell Res.200212191810.1038/sj.cr.729010511942415
     [Google Scholar]
  52. HossiniA.M. QuastA.S. PlötzM. GrauelK. ExnerT. KüchlerJ. StachelscheidH. EberleJ. RabienA. MakrantonakiE. ZouboulisC.C. PI3K/AKT signaling pathway is essential for survival of induced pluripotent stem cells.PLoS One2016115e015477010.1371/journal.pone.015477027138223
     [Google Scholar]
  53. HabibA.A. ChatterjeeS. ParkS.K. RatanR.R. LefebvreS. VartanianT. The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF-kappa B. Identification of a novel receptor-tyrosine kinase signalosome.J. Biol. Chem.2001276128865887410.1074/jbc.M008458200
     [Google Scholar]
  54. TakahashiM. Yamamoto-FukudaT. AkiyamaN. MotegiM. YamamotoK. TanakaY. YamamotoY. KojimaH. Partial epithelial-mesenchymal transition was observed under p63 expression in acquired middle ear cholesteatoma and congenital cholesteatoma.Otol. Neurotol.2019408e803e81110.1097/MAO.000000000000232831348131
     [Google Scholar]
  55. HuismanM.A. de HeerE. DijkeP.T. GroteJ.J. Transforming growth factor beta and wound healing in human cholesteatoma.Laryngoscope20081181949810.1097/MLG.0b013e31814faafa17989584
     [Google Scholar]
  56. ZengL. XieL. HuJ. HeC. LiuA. LuX. ZhouW. Osteopontin-driven partial epithelial-mesenchymal transition governs the development of middle ear cholesteatoma.Cell Cycle202423553755410.1080/15384101.2024.234548138662954
     [Google Scholar]
  57. TakeichiM. Cadherin cell adhesion receptors as a morphogenetic regulator.Science199125150001451145510.1126/science.20064192006419
     [Google Scholar]
  58. LeeD.W. ChungJ.H. LeeS.H. ParkC.W. KangS.H. OhY.H. PyoJ.Y. Comparative analysis of the expression of E-cadherin, β-catenin, and β1 integrin in congenital and acquired cholesteatoma.Eur. Arch. Otorhinolaryngol.2016273484585110.1007/s00405‑015‑3621‑x25864182
     [Google Scholar]
  59. van der WalT. van AmerongenR. Walking the tight wire between cell adhesion and WNT signalling: A balancing act for β-catenin.Open Biol.2020101220026710.1098/rsob.20026733292105
     [Google Scholar]
  60. AzbazdarY. KarabiciciM. ErdalE. OzhanG. Regulation of Wnt signaling pathways at the plasma membrane and their misregulation in cancer.Front. Cell Dev. Biol.2021963162310.3389/fcell.2021.63162333585487
     [Google Scholar]
  61. GiancottiF.G. RuoslahtiE. Integrin Signaling.Science199928554301028103310.1126/science.285.5430.102810446041
     [Google Scholar]
  62. DallariS. CavaniA. BergaminiG. GirolomoniG. Integrin expression in middle ear cholesteatoma.Acta Otolaryngol.1994114218819210.3109/000164894091260407515549
     [Google Scholar]
  63. AmbrosV. The functions of animal microRNAs.Nature2004431700635035510.1038/nature0287115372042
     [Google Scholar]
  64. ChenX. QinZ. Post-transcriptional regulation by microrna-21 and let-7a microRNA in paediatric cholesteatoma.J. Int. Med. Res.20113962110211810.1177/14732300110390060722289526
     [Google Scholar]
  65. FriedlandD.R. EernisseR. ErbeC. GuptaN. CioffiJ.A. Cholesteatoma growth and proliferation: Posttranscriptional regulation by microRNA-21.Otol. Neurotol.2009307998100510.1097/MAO.0b013e3181b4e91f19672202
     [Google Scholar]
  66. YaoR. MaY.L. LiangW. LiH.H. MaZ.J. YuX. LiaoY.H. MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1.PLoS One2012710e4608210.1371/journal.pone.004608223091595
     [Google Scholar]
  67. LenaA.M. Shalom-FeuersteinR. di Val CervoP.R. AberdamD. KnightR.A. MelinoG. CandiE. miR-203 represses ‘stemness’ by repressing ΔNp63.Cell Death Differ.20081571187119510.1038/cdd.2008.6918483491
     [Google Scholar]
  68. KasinathanJ.R. MuthukkaruppanV. PriyaC.G. miR-203 inhibits ΔNp63α dependent clonogenicity in corneal epithelial stem cells (CESCs).Invest. Ophthalmol. Vis. Sci.20155648994899
     [Google Scholar]
  69. WangM-J. XuY-Y. VosH. GulersonmezC. StigterE. GerritsenJ. Hsa-miR-31-5p controls a metabolic switch in psoriatic keratinocytes that identifies therapeutic intervention.bioRxiv202210.1101/2022.01.21.477183
     [Google Scholar]
  70. BarduaM. HaftmannC. DurekP. WestendorfK. ButtgereitA. TranC.L. McGrathM. WeberM. LehmannK. AddoR.K. HeinzG.A. StittrichA.B. MaschmeyerP. RadbruchH. LohoffM. ChangH.D. RadbruchA. MashreghiM.F. MicroRNA-31 reduces the motility of proinflammatory T helper 1 lymphocytes.Front. Immunol.20189281310.3389/fimmu.2018.0281330574141
     [Google Scholar]
  71. MIR31 microRNA 31 [ Homo sapiens (human) ].Available from: https://www.ncbi.nlm.nih.gov/gene/407035
  72. YangF. LiQ. GongZ. ZhouL. YouN. WangS. LiX. LiJ. AnJ. WangD. HeY. DouK. MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment.Technol. Cancer Res. Treat.2014131778610.7785/tcrt.2012.50036423862748
     [Google Scholar]
  73. InghamP.W. Hedgehog signaling.Curr. Top. Dev. Biol.202214915810.1016/bs.ctdb.2022.04.00335606054
     [Google Scholar]
  74. DambergsK. SumeragaG. PilmaneM. Complex evaluation of tissue factors in pediatric cholesteatoma.Children202181092610.3390/children810092634682191
     [Google Scholar]
  75. DambergsK. SumeragaG. PilmaneM. Comparison of tissue factors in the ontogenetic aspects of human cholesteatoma.Diagnostics202414666210.3390/diagnostics1406066238535082
     [Google Scholar]
  76. PalkóE. PóliskaS. CsákányiZ. KatonaG. KarosiT. HelfferichF. PenyigeA. SziklaiI. The c-MYC protooncogene expression in cholesteatoma.BioMed Res. Int.201420141610.1155/2014/63989624683550
     [Google Scholar]
  77. OzturkK. YildirimM.S. AcarH. CenikZ. KelesB. Evaluation of c-MYC status in primary acquired cholesteatoma by using fluorescence in situ hybridization technique.Otol. Neurotol.200627558859110.1097/01.mao.0000226290.04048.d916868505
     [Google Scholar]
  78. LiY.J. WeiZ-M. MengY-X. JiX-R. β-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: Relationships with carcinogenesis and metastasis.World J. Gastroenterol.200511142117212310.3748/wjg.v11.i14.211715810077
     [Google Scholar]
  79. LuQ. HongW. Bcl2 enhances c-Myc-mediated MMP-2 expression of vascular smooth muscle cells.Cell. Signal.20092171054105910.1016/j.cellsig.2009.02.02019258038
     [Google Scholar]
  80. SchürmannM. GreinerJ.F.W. Volland-ThurnV. OppelF. KaltschmidtC. SudhoffH. KaltschmidtB. Stem cell-induced inflammation in cholesteatoma is inhibited by the TLR4 antagonist LPS-RS.Cells20209119910.3390/cells901019931947538
     [Google Scholar]
  81. SehnertB. BurkhardtH. WesselsJ.T. SchröderA. MayM.J. VestweberD. ZwerinaJ. WarnatzK. NimmerjahnF. SchettG. DübelS. VollR.E. NF-κB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-κB in immune-mediated diseases.Proc. Natl. Acad. Sci. USA201311041165561656110.1073/pnas.121821911024062461
     [Google Scholar]
  82. BodyJ.J. BoneH.G. de BoerR.H. StopeckA. Van PoznakC. DamiãoR. FizaziK. HenryD.H. IbrahimT. LiptonA. SaadF. ShoreN. TakanoT. ShaywitzA.J. WangH. BraccoO.L. BraunA. KostenuikP.J. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.Eur. J. Cancer201551131812182110.1016/j.ejca.2015.05.01626093811
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673404489250515074316
Loading
Cholesteatoma: An Updated Review of Molecular Pathogenesis and Potential Therapeutic Directions
Curr. Med. Chem. 33, 616 (2026); https://doi.org/10.2174/0109298673404489250515074316
/content/journals/cmc/10.2174/0109298673404489250515074316
/content/journals/cmc/10.2174/0109298673404489250515074316
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): bone resorption; Cholesteatoma; inflammation; molecular mechanism; pathogenesis; therapy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test